Rare Biomarkers Specimen Collection And Stabilization Market Growth & Trends
The global rare biomarkers specimen collection and stabilization market size is expected to reach USD 92.39 billion by 2030, expanding at a CAGR of 14.4% from 2025 to 2030. Expanding potential applications of circulating rare biomarkers has created lucrative opportunities for the technology developers that are engaged in the introduction of products to support the effective and rapid collection and stabilization of these rare biomarkers specimen. Furthermore, the emergence of liquid biopsy for cancer screening, diagnosis, prognosis, and treatment monitoring has significantly enhanced the competition and capabilities in the market for rare biomarkers specimen collection and stabilization, thereby aiding in revenue growth.
Given the potential of circulating biomarkers, both as high-value therapy delivery systems and as potential diagnostics, researchers are adopting more sensitive, rapid, and flexible analytical tools. Key players are developing novel technologies and products for collection and stabilization of these rare biomarkers specimen to expand research possibilities. Despite a substantial number of advantages, there are still challenges to overcome their clinical application.
Although most of the isolation methods are highly specific and sensitive, thus far, there is lack of sufficient evidence on the use and efficacy of the products in clinical samples. This hampers the clinical use of rare biomarkers specimen because differences in analytical sensitivity between these methods play a very crucial role. However, an increase in studies on the clinical utility of these rare biomarkers specimen is anticipated to effectively address the clinical implementation-related challenges.
Rare Biomarkers Specimen Collection And Stabilizations Market Report Highlights
- The circulating cell-free DNA (ccfDNA) segment accounted for the largest share of the market at 36.0% in 2024.
- The research segment captured the highest share of 74.1% in 2024. The dominance of the rare biomarker segment is largely due to the growing number of research studies focused on their implementation.
- The diagnostics segment expected to expand at the CAGR of 15.0% by 2030. While rare biomarkers such as Circulating Cell-Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and exosomes have primarily been used in research settings, they are increasingly being explored for diagnostic applications.
- North America rare biomarkers specimen collection and stabilization industry dominated and accounted for a 52.1% share in 2024.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Biomarker
1.2.2. End Use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
1.2. Segment Definitions
1.2.1. Biomarker
1.2.2. End Use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Biomarker outlook
2.2.2. End use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
2.2. Segment Outlook
2.2.1. Biomarker outlook
2.2.2. End use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Rare Biomarkers Specimen Collection and Stabilization Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising Demand for Precision Medicine
3.2.1.2. Advancements in Liquid Biopsy Technologies
3.2.1.3. Increasing Prevalence of Chronic and Genetic Diseases
3.2.2. Market restraint analysis
3.2.2.1. High Costs
3.2.2.2. Lack of Standardization
3.3. Rare Biomarkers Specimen Collection and Stabilization Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising Demand for Precision Medicine
3.2.1.2. Advancements in Liquid Biopsy Technologies
3.2.1.3. Increasing Prevalence of Chronic and Genetic Diseases
3.2.2. Market restraint analysis
3.2.2.1. High Costs
3.2.2.2. Lack of Standardization
3.3. Rare Biomarkers Specimen Collection and Stabilization Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Rare Biomarkers Specimen Collection and Stabilization Market: Biomarker Estimates & Trend Analysis
4.1. Biomarker Market Share, 2024 & 2030
4.2. Segment Dashboard
4.3. Global Rare Biomarkers Specimen Collection and Stabilization Market by Biomarker Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Circulating Cell Free DNA (ccfDNA)
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.2. Circulating Tumor Cells (CTCs)
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3. Exosomes/Extracellular Vesicles
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.2. By Product
4.4.3.2.1. Isolation Kits & Reagents
4.4.3.2.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.2.2. Blood Collection Tubes
4.4.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.2.3. Systems
4.4.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.3. By Specimen Type
4.4.3.3.1. Serum/Plasma
4.4.3.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.3.2. Others
4.4.3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.4. By Nucleic Acid & Other Biomolecules
4.4.3.4.1. RNA
4.4.3.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.4.2. DNA
4.4.3.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.4.3. Others
4.4.3.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5. By Application
4.4.3.5.1. NIPT
4.4.3.5.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5.2. Oncology
4.4.3.5.3. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5.3.1. Research
4.4.3.5.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5.3.2. Diagnostics
4.4.3.5.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5.3.2.2. Screening
4.4.3.5.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5.3.2.3. Treatment Monitoring
4.4.3.5.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5.4. Transcriptomics
4.4.3.5.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5.5. Pharmacogenomics
4.4.3.5.5.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5.6. Transplant Rejection
4.4.3.5.6.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5.7. Population Screening
4.4.3.5.7.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5.8. Cardiovascular Diseases
4.4.3.5.8.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5.9. Other Applications
4.4.3.5.9.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4. Circulating Cell Free RNA (ccfRNA) / miRNA
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.2. By Product
4.4.4.2.1. Isolation Kits & Reagents
4.4.4.2.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.2.2. Blood Collection Tubes
4.4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.3. By Application
4.4.4.3.1. NIPT
4.4.4.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.3.2. Oncology
4.4.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.3.2.2. Research
4.4.4.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.3.2.3. Diagnostics
4.4.4.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.3.3. Transcriptomics
4.4.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.3.4. Pharmacogenomics
4.4.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.3.5. Transplant Rejection
4.4.4.3.5.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.3.6. Population Screening
4.4.4.3.6.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.3.7. Cardiovascular Diseases
4.4.4.3.7.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.3.8. Other Applications
4.4.4.3.8.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.2. Segment Dashboard
4.3. Global Rare Biomarkers Specimen Collection and Stabilization Market by Biomarker Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Circulating Cell Free DNA (ccfDNA)
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.2. Circulating Tumor Cells (CTCs)
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3. Exosomes/Extracellular Vesicles
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.2. By Product
4.4.3.2.1. Isolation Kits & Reagents
4.4.3.2.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.2.2. Blood Collection Tubes
4.4.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.2.3. Systems
4.4.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.3. By Specimen Type
4.4.3.3.1. Serum/Plasma
4.4.3.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.3.2. Others
4.4.3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.4. By Nucleic Acid & Other Biomolecules
4.4.3.4.1. RNA
4.4.3.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.4.2. DNA
4.4.3.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.4.3. Others
4.4.3.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5. By Application
4.4.3.5.1. NIPT
4.4.3.5.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5.2. Oncology
4.4.3.5.3. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5.3.1. Research
4.4.3.5.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5.3.2. Diagnostics
4.4.3.5.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5.3.2.2. Screening
4.4.3.5.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5.3.2.3. Treatment Monitoring
4.4.3.5.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5.4. Transcriptomics
4.4.3.5.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5.5. Pharmacogenomics
4.4.3.5.5.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5.6. Transplant Rejection
4.4.3.5.6.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5.7. Population Screening
4.4.3.5.7.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5.8. Cardiovascular Diseases
4.4.3.5.8.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.3.5.9. Other Applications
4.4.3.5.9.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4. Circulating Cell Free RNA (ccfRNA) / miRNA
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.2. By Product
4.4.4.2.1. Isolation Kits & Reagents
4.4.4.2.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.2.2. Blood Collection Tubes
4.4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.3. By Application
4.4.4.3.1. NIPT
4.4.4.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.3.2. Oncology
4.4.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.3.2.2. Research
4.4.4.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.3.2.3. Diagnostics
4.4.4.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.3.3. Transcriptomics
4.4.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.3.4. Pharmacogenomics
4.4.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.3.5. Transplant Rejection
4.4.4.3.5.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.3.6. Population Screening
4.4.4.3.6.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.3.7. Cardiovascular Diseases
4.4.4.3.7.1. Market estimates and forecasts 2018 to 2030 (USD million)
4.4.4.3.8. Other Applications
4.4.4.3.8.1. Market estimates and forecasts 2018 to 2030 (USD million)
Chapter 5. Rare Biomarkers Specimen Collection and Stabilization Market: End Use Estimates & Trend Analysis
5.1. End Use Market Share, 2024 & 2030
5.2. Segment Dashboard
5.3. Global Rare Biomarkers Specimen Collection and Stabilization Market by End Use Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Research
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
5.4.1.2. Research Labs/CROs
5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3. Academic Institutes
5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Diagnostics
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.2. Laboratories
5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.3. Hospitals
5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.4. Prenatal clinics
5.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.2. Segment Dashboard
5.3. Global Rare Biomarkers Specimen Collection and Stabilization Market by End Use Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Research
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
5.4.1.2. Research Labs/CROs
5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3. Academic Institutes
5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Diagnostics
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.2. Laboratories
5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.3. Hospitals
5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.4. Prenatal clinics
5.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Rare Biomarkers Specimen Collection and Stabilization Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
6.5. North America
6.5.1. U.S.
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. Canada
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. Mexico
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million
6.6. Europe
6.6.1. UK
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.6.2. Germany
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.6.3. France
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework/ reimbursement structure
6.6.3.3. Competitive scenario
6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.6.4. Italy
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework/ reimbursement structure
6.6.4.3. Competitive scenario
6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.6.5. Spain
6.6.5.1. Key country dynamics
6.6.5.2. Regulatory framework/ reimbursement structure
6.6.5.3. Competitive scenario
6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.6.6. Norway
6.6.6.1. Key country dynamics
6.6.6.2. Regulatory framework/ reimbursement structure
6.6.6.3. Competitive scenario
6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.6.7. Sweden
6.6.7.1. Key country dynamics
6.6.7.2. Regulatory framework/ reimbursement structure
6.6.7.3. Competitive scenario
6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.6.8. Denmark
6.6.8.1. Key country dynamics
6.6.8.2. Regulatory framework/ reimbursement structure
6.6.8.3. Competitive scenario
6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Asia Pacific
6.7.1. Japan
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.7.2. China
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.7.3. India
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.7.4. Australia
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.7.5. South Korea
6.7.5.1. Key country dynamics
6.7.5.2. Regulatory framework/ reimbursement structure
6.7.5.3. Competitive scenario
6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.7.6. Thailand
6.7.6.1. Key country dynamics
6.7.6.2. Regulatory framework/ reimbursement structure
6.7.6.3. Competitive scenario
6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.8. Latin America
6.8.1. Brazil
6.8.1.1. Key country dynamics
6.8.1.2. Regulatory framework/ reimbursement structure
6.8.1.3. Competitive scenario
6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.8.1.5. )
6.8.2. Argentina
6.8.2.1. Key country dynamics
6.8.2.2. Regulatory framework/ reimbursement structure
6.8.2.3. Competitive scenario
6.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.9. MEA
6.9.1. South Africa
6.9.1.1. Key country dynamics
6.9.1.2. Regulatory framework/ reimbursement structure
6.9.1.3. Competitive scenario
6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.9.2. Saudi Arabia
6.9.2.1. Key country dynamics
6.9.2.2. Regulatory framework/ reimbursement structure
6.9.2.3. Competitive scenario
6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.9.3. UAE
6.9.3.1. Key country dynamics
6.9.3.2. Regulatory framework/ reimbursement structure
6.9.3.3. Competitive scenario
6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.9.4. Kuwait
6.9.4.1. Key country dynamics
6.9.4.2. Regulatory framework/ reimbursement structure
6.9.4.3. Competitive scenario
6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
6.5. North America
6.5.1. U.S.
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. Canada
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. Mexico
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million
6.6. Europe
6.6.1. UK
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.6.2. Germany
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.6.3. France
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework/ reimbursement structure
6.6.3.3. Competitive scenario
6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.6.4. Italy
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework/ reimbursement structure
6.6.4.3. Competitive scenario
6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.6.5. Spain
6.6.5.1. Key country dynamics
6.6.5.2. Regulatory framework/ reimbursement structure
6.6.5.3. Competitive scenario
6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.6.6. Norway
6.6.6.1. Key country dynamics
6.6.6.2. Regulatory framework/ reimbursement structure
6.6.6.3. Competitive scenario
6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.6.7. Sweden
6.6.7.1. Key country dynamics
6.6.7.2. Regulatory framework/ reimbursement structure
6.6.7.3. Competitive scenario
6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.6.8. Denmark
6.6.8.1. Key country dynamics
6.6.8.2. Regulatory framework/ reimbursement structure
6.6.8.3. Competitive scenario
6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Asia Pacific
6.7.1. Japan
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.7.2. China
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.7.3. India
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.7.4. Australia
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.7.5. South Korea
6.7.5.1. Key country dynamics
6.7.5.2. Regulatory framework/ reimbursement structure
6.7.5.3. Competitive scenario
6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.7.6. Thailand
6.7.6.1. Key country dynamics
6.7.6.2. Regulatory framework/ reimbursement structure
6.7.6.3. Competitive scenario
6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.8. Latin America
6.8.1. Brazil
6.8.1.1. Key country dynamics
6.8.1.2. Regulatory framework/ reimbursement structure
6.8.1.3. Competitive scenario
6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.8.1.5. )
6.8.2. Argentina
6.8.2.1. Key country dynamics
6.8.2.2. Regulatory framework/ reimbursement structure
6.8.2.3. Competitive scenario
6.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.9. MEA
6.9.1. South Africa
6.9.1.1. Key country dynamics
6.9.1.2. Regulatory framework/ reimbursement structure
6.9.1.3. Competitive scenario
6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.9.2. Saudi Arabia
6.9.2.1. Key country dynamics
6.9.2.2. Regulatory framework/ reimbursement structure
6.9.2.3. Competitive scenario
6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.9.3. UAE
6.9.3.1. Key country dynamics
6.9.3.2. Regulatory framework/ reimbursement structure
6.9.3.3. Competitive scenario
6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.9.4. Kuwait
6.9.4.1. Key country dynamics
6.9.4.2. Regulatory framework/ reimbursement structure
6.9.4.3. Competitive scenario
6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. Key company market share analysis, 2024
7.3.2. QIAGEN
7.3.2.1. Company overview
7.3.2.2. Financial performance
7.3.2.3. Product benchmarking
7.3.2.4. Strategic initiatives
7.3.3. Charles River Laboratories
7.3.3.1. Company overview
7.3.3.2. Financial performance
7.3.3.3. Product benchmarking
7.3.3.4. Strategic initiatives
7.3.4. F. Hoffmann-La Roche Ltd
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Terumo Medical Corp
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. Thermofischer Scientific Inc
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Eurofins Scientific
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. PerkinElmer Inc
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Bio-Rad Laboratories, Inc
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Agilent Technologies, Inc
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. Merck KGaA
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. Siemens Healthcare GmbH
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. Key company market share analysis, 2024
7.3.2. QIAGEN
7.3.2.1. Company overview
7.3.2.2. Financial performance
7.3.2.3. Product benchmarking
7.3.2.4. Strategic initiatives
7.3.3. Charles River Laboratories
7.3.3.1. Company overview
7.3.3.2. Financial performance
7.3.3.3. Product benchmarking
7.3.3.4. Strategic initiatives
7.3.4. F. Hoffmann-La Roche Ltd
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Terumo Medical Corp
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. Thermofischer Scientific Inc
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Eurofins Scientific
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. PerkinElmer Inc
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Bio-Rad Laboratories, Inc
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Agilent Technologies, Inc
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. Merck KGaA
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. Siemens Healthcare GmbH
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
List of Tables
Table 1 List of Abbreviations
Table 2 North America rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 3 North America rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 4 North America rare biomarkers specimen collection and stabilization market, by country, 2018 - 2030 (USD Million)
Table 5 U.S. rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 6 U.S. rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 7 Canada rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 8 Canada rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 9 Mexico rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 10 Mexico rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 11 Europe rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 12 Europe rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 13 Europe rare biomarkers specimen collection and stabilization market, by country, 2018 - 2030 (USD Million)
Table 14 Germany rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 15 Germany rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 16 UK rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 17 UK rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 18 France rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 19 France rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 20 Italy rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 21 Italy rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 22 Spain rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 23 Spain rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 24 Sweden rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 25 Sweden rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 26 Norway rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 27 Norway rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 28 Denmark rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 29 Denmark rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 30 Asia Pacific rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 31 Asia Pacific rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 32 Asia Pacific rare biomarkers specimen collection and stabilization market, by country, 2018 - 2030 (USD Million)
Table 33 China rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 34 China rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 35 Japan rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 36 Japan rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 37 India rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 38 India rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 39 Australia rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 40 Australia rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 41 Thailand rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 42 Thailand rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 43 South Korea rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 44 South Korea rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 45 Latin America rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 46 Latin America rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 47 Latin America rare biomarkers specimen collection and stabilization market, by country, 2018 - 2030 (USD Million)
Table 48 Brazil rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 49 Brazil rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 50 Argentina rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 51 Argentina rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 52 Middle East and Africa rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 53 Middle East and Africa rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 54 Middle East and Africa rare biomarkers specimen collection and stabilization market, by country, 2018 - 2030 (USD Million)
Table 55 South Africa rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 56 South Africa rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 57 Saudi Arabia rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 59 UAE rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 60 UAE rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 61 Kuwait rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 62 Kuwait rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 2 North America rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 3 North America rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 4 North America rare biomarkers specimen collection and stabilization market, by country, 2018 - 2030 (USD Million)
Table 5 U.S. rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 6 U.S. rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 7 Canada rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 8 Canada rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 9 Mexico rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 10 Mexico rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 11 Europe rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 12 Europe rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 13 Europe rare biomarkers specimen collection and stabilization market, by country, 2018 - 2030 (USD Million)
Table 14 Germany rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 15 Germany rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 16 UK rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 17 UK rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 18 France rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 19 France rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 20 Italy rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 21 Italy rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 22 Spain rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 23 Spain rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 24 Sweden rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 25 Sweden rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 26 Norway rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 27 Norway rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 28 Denmark rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 29 Denmark rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 30 Asia Pacific rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 31 Asia Pacific rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 32 Asia Pacific rare biomarkers specimen collection and stabilization market, by country, 2018 - 2030 (USD Million)
Table 33 China rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 34 China rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 35 Japan rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 36 Japan rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 37 India rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 38 India rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 39 Australia rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 40 Australia rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 41 Thailand rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 42 Thailand rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 43 South Korea rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 44 South Korea rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 45 Latin America rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 46 Latin America rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 47 Latin America rare biomarkers specimen collection and stabilization market, by country, 2018 - 2030 (USD Million)
Table 48 Brazil rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 49 Brazil rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 50 Argentina rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 51 Argentina rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 52 Middle East and Africa rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 53 Middle East and Africa rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 54 Middle East and Africa rare biomarkers specimen collection and stabilization market, by country, 2018 - 2030 (USD Million)
Table 55 South Africa rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 56 South Africa rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 57 Saudi Arabia rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 59 UAE rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 60 UAE rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
Table 61 Kuwait rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
Table 62 Kuwait rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Rare Biomarkers Specimen Collection and Stabilization: Market outlook
Fig. 9 rare biomarkers specimen collection and stabilization competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 rare biomarkers specimen collection and stabilization market driver impact
Fig. 15 rare biomarkers specimen collection and stabilization market restraint impact
Fig. 16 rare biomarkers specimen collection and stabilization market strategic initiatives analysis
Fig. 17 rare biomarkers specimen collection and stabilization market: Biomarker movement analysis
Fig. 18 rare biomarkers specimen collection and stabilization market: Biomarker outlook and key takeaways
Fig. 19 rare biomarkers specimen collection and stabilization market: End Use movement analysis
Fig. 20 rare biomarkers specimen collection and stabilization market: End Use outlook and key takeaways
Fig. 21 Circulating Cell Free DNA (ccfDNA) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Circulating Tumor Cells (CTCs) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Exosomes/Extracellular Vesicles market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Isolation kits & reagents market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Blood collection tubes market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Systems market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Serum/Plasma market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Nucleic acid & other biomolecules market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 RNA market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 DNA market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 NIPT market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Research market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Screening market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Treatment monitoring market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Transcriptomics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Pharmacogenomics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Transplant rejection market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Population screening market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Cardiovascular diseases market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Other applications market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Circulating Cell Free RNA (ccfRNA) / miRNA market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Blood collection tubes market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 NIPT market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Research market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Transcriptomics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Pharmacogenomics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Transplant rejection market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Population screening market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Cardiovascular diseases market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Other applications market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Research market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Research labs/CROs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Prenatal clinics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Global rare biomarkers specimen collection and stabilization market: Regional movement analysis
Fig. 65 Global rare biomarkers specimen collection and stabilization market: Regional outlook and key takeaways
Fig. 66 North America rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 U.S. rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Canada rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 Europe rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 UK rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 Germany rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 France rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Italy rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 Spain rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 75 Sweden rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 76 Norway rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Denmark rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 78 Asia Pacific rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Japan rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 China rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 India rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 82 Australia rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 Thailand rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 South Korea rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 85 Latin America rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Brazil rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 87 Mexico rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 88 Argentina rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 89 Middle East and Africa rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 90 Saudi Arabia rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 91 South Africa rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 92 UAE rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 93 Kuwait rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Rare Biomarkers Specimen Collection and Stabilization: Market outlook
Fig. 9 rare biomarkers specimen collection and stabilization competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 rare biomarkers specimen collection and stabilization market driver impact
Fig. 15 rare biomarkers specimen collection and stabilization market restraint impact
Fig. 16 rare biomarkers specimen collection and stabilization market strategic initiatives analysis
Fig. 17 rare biomarkers specimen collection and stabilization market: Biomarker movement analysis
Fig. 18 rare biomarkers specimen collection and stabilization market: Biomarker outlook and key takeaways
Fig. 19 rare biomarkers specimen collection and stabilization market: End Use movement analysis
Fig. 20 rare biomarkers specimen collection and stabilization market: End Use outlook and key takeaways
Fig. 21 Circulating Cell Free DNA (ccfDNA) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Circulating Tumor Cells (CTCs) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Exosomes/Extracellular Vesicles market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Isolation kits & reagents market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Blood collection tubes market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Systems market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Serum/Plasma market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Nucleic acid & other biomolecules market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 RNA market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 DNA market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 NIPT market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Research market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Screening market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Treatment monitoring market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Transcriptomics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Pharmacogenomics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Transplant rejection market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Population screening market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Cardiovascular diseases market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Other applications market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Circulating Cell Free RNA (ccfRNA) / miRNA market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Blood collection tubes market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 NIPT market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Research market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Transcriptomics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Pharmacogenomics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Transplant rejection market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Population screening market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Cardiovascular diseases market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Other applications market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Research market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Research labs/CROs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Prenatal clinics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Global rare biomarkers specimen collection and stabilization market: Regional movement analysis
Fig. 65 Global rare biomarkers specimen collection and stabilization market: Regional outlook and key takeaways
Fig. 66 North America rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 U.S. rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Canada rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 Europe rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 UK rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 Germany rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 France rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Italy rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 Spain rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 75 Sweden rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 76 Norway rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Denmark rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 78 Asia Pacific rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Japan rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 China rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 India rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 82 Australia rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 Thailand rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 South Korea rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 85 Latin America rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Brazil rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 87 Mexico rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 88 Argentina rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 89 Middle East and Africa rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 90 Saudi Arabia rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 91 South Africa rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 92 UAE rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 93 Kuwait rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
Companies Mentioned
- QIAGEN
- Charles River Laboratories
- F. Hoffmann-La Roche Ltd
- Thermo fischer Scientific Inc.
- Eurofins Scientific
- PerkinElmer Inc.
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc
- Merck KGaA
- Siemens Healthcare GmbH
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | December 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 41.97 billion |
| Forecasted Market Value ( USD | $ 92.39 billion |
| Compound Annual Growth Rate | 14.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
